International Workshop on Clinical Pharmacology of TB Drugs

Welcome

We are pleased to announce that the 15th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place 1-2 October 2024 as a virtual meeting.

This abstract-driven workshop has been the leading annual meeting in the tuberculosis (TB) pharmacology field since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for presentation and discussion of the latest scientific developments in the TB pharmacology field.

If you work in the field of TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, PhD students; and representatives from regulatory or non-governmental organizations active in the TB-field.

The program consists of e-poster abstract presentations. The workshop is informal in setting and is meant to be interactive.

We look forward to seeing you virtually this October!

On behalf of the Organizing Committee,

15th International Workshop on Clinical Pharmacology of Tuberculosis Drugs
Virtual Meeting, 1-2 October, 2024

Lectures	Speakers	Presentations	Abstracts
DAY 1 Tuesday 1 October
Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs
Chairs: Jerry Nedelman & Eric Nuermberger
Model-informed once-daily dosing strategy for bedaquiline and delamanid in children, adolescents and adults with tuberculosis	Yu-Jou Lin		Abstract
Linezolid dosing and pharmacokinetics in North American patients with tuberculosis, 2019-2023	Nicole Maranchick		Abstract
Pharmacogenetics and pharmacokinetics of moxifloxacin in MDR-TB patients in Indonesia: analysis for ABCB1 rs2032582 and SLCO1B1	Nurul Annisa		Abstract
Delpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis	Isabella van der Feltz		Abstract

Session 2 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB meningitis)
Chairs: Caitlin Reed & Christine Sekaggya-Wiltshire
Pharmacokinetic modelling of rifampicin, isoniazid, pyrazinamide, linezolid and rifabutin in CNS tissues: a rabbit model study of tuberculosis meningitis	Noha Adbelgawad		Abstract
Pharmacokinetic analysis of isoniazid and dexamethasone in adults with tuberculosis meningitis	Jose Miguel Calderin Miranda		Abstract
Pharmacokinetics and safety/tolerability of linezolid in Indonesian TB meningitis patients	Lindsey te Brake
Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs	Xueyi Chen		Abstract
Rapporteur session	Rob Aarnoutse

Session 3 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB in pregnancy, children, extrapulmonary TB, NTM disease)
Chairs: Nicole Maranchick & Ulrika Simonsson
Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy	Sharon Sawe		Abstract
Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis	Yuanxi Zou		Abstract
Lower dose-adjusted concentrations of rifampicin and pyrazinamide in pulmonary versus extra-pulmonary tuberculosis	Gustav Svärdhagen		Abstract
A loading dose of clofazimine to optimize treatment in patients with nontuberculous mycobacterial diseases	Ralf Stemkens		Abstract
Rapporteur session	Charles Peloquin

DAY 2 Wednesday 2 October
Session 4 Approaches and tools in TB drug development and optimization and in treatment of patients
Chairs: Gerry Davies & Charles Peloquin
Advancing tuberculosis therapy with co-crystals: a comprehensive review	Shagun Gogna		Abstract
Using machine learning to expedite area under the curve calculation for PK/PD analysis	Abdullah Alsultan		Abstract
Machine-learning time-to-event analysis for prediction of 2-month culture conversion with phase 2a information in tuberculosis drug development	Huifang You		Abstract
On our way to personalized therapy: using therapeutic drug monitoring of moxifloxacin for an external pharmacokinetic model evaluation	Emily Behrens		Abstract
Evaluation of QT prolongation during bedaquiline treatment using a time-varying tuberculosis-specific correction factor (QTcTBT)	Thanakorn Vongjarudech		Abstract

14th International Workshop on Clinical Pharmacology of Tuberculosis Drugs
Virtual Meeting, 26-27 September, 2023

Lectures	Speakers	Presentations	Abstracts	Posters
DAY 1 Tuesday 26 September
Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs
Chairs: Helen McIlleron & Eric Nuermberger
Invited lecture. New oxazolidinones: lessons learned about sutezolid and delpazolid	Norbert Heinrich
Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis	Simon Koele		Abstract
TBAJ-587 and ERA4TB: a productive clinical development partnership	Almari Conradie		Abstract
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis	Ralf Stemkens		Abstract
Delpazolid population pharmacokinetics in patients with pulmonary tuberculosis	Isabella van der Feltz		Abstract

Session 2 Patient populations: pharmacological aspects of specific forms of TB
Chairs: Jerry Nedelman & Ulrika Simonsson
Invited lecture. Insights on TB meningitis treatment from animal models and advanced imaging techniques	Sanjay Jain
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of multidrug-resistant tuberculosis in Indonesia	Vycke Yunivita & Fajri Gafar		Abstract
The association between drug exposure, susceptibility and response and clinical thresholds for pyrazinamide in MDR-TB treatment	Shulan Dong		Abstract
Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy	Manna Semere Gebreyesus		Abstract
Effect of pregnancy on population pharmacokinetics of levofloxacin in South African adults with rifampicin-resistant tuberculosis	Sharon Sawe		Abstract

Session 3 Short presentations & pitches for poster viewing
Chair: Geraint Davies
Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations	Budi Octasari Susanto		Abstract
A study of the drug interaction potential of TBAJ-876 on CYP3A4 and P-gp substrates in healthy adults	Jerry Nedelman		Abstract	Poster
Pharmacokinetics of levofloxacin during pregnancy and post-partum in persons living with HIV and without HIV and receiving treatment for rifampicin-resistant	Jennifer Hughes		Abstract	Poster
Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis	Noha Abdelgawad		Abstract	Poster
Population pharmacokinetic modelling of pyrazinamide in plasma and cerebrospinal fluid from HIV-associated tuberculosis meningitis adults	Jose Miguel Calderin		Abstract	Poster
Limited sampling strategy and dose evaluation for second-line anti-tuberculosis drugs in patients with type II diabetes mellitus	Jiayi Cao		Abstract	Poster
Evaluating two strategies for the design of pediatric pharmacokinetic studies	Yuanxi Zou		Abstract	Poster

DAY 2 Wednesday 27 September
Session 4 The role of consortia in TB drug development
Chairs: Rob Aarnoutse & Charles Peloquin
ERA4TB	Santiago Ferrer Bazaga
Unite4TB	Martin Boeree
PAN-TB	Charles Wells
Panel discussion on preselected topics & propositions		Coming Soon

Session 5 Approaches and tools in TB drug development and optimization and in treatment of patients
Chairs: Susan Swindells & Paolo Denti
Higher-order combination drug regimens and pharmacodynamic markers of response in a mouse tuberculosis infection model	Michael Lyons		Abstract
Power to identify exposure-response relationships in phase IIa tuberculosis trials with multi-dimensional bacterial load modeling	Simon Koele		Abstract
Development of a PBPK model for TBAJ-876 within the SIMCYP population-based simulator and subsequent evaluation of DDI liability as a victim of CYP3A4	Ludwig Vincent		Abstract
Drug-drug interaction management of bedaquiline and other medications associated with QT-interval prolongation	David Burger		Abstract
Rifampin dosing and pharmacokinetics from an international TDM service, 2022	Nicole Maranchick		Abstract
Saliva-based assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer	Ricky Chen		Abstract

Session 6 Short presentations & pitches for poster viewing
Chair: Jerry Nedelman
Co-crystals for tuberculosis	Shagun Gogna		Abstract	Poster
4β-hydroxycholesterol-to-cholesterol ratio as an endogenous biomarker in human plasma to determine treatment effects of induction and inhibition of CYP3A4	Yashara Ryan		Abtract	Poster
Population pharmacokinetics of pretomanid in participants of a randomised controlled clinical trial for rifampicin-resistant tuberculosis	Bern-Thomas Nyang'wa		Abstract	Poster
Population pharmacokinetics of clofazimine in a randomised controlled clinical trial for rifampicin-resistant tuberculosis	Ilaria Motta			Poster
Physico-chemical properties influencing penetration into saliva: a systematic review	Anh Thi Nguyen		Abstract	Poster
Analysis of time to positivity of Mycobacterium tuberculosis in response to treatment for drug susceptible tuberculosis in South African patients	Marie Wijk		Abstract	Poster

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2024

Welcome

2024 materials

2023 materials